Median time to first supportive therapy was 5 months for GB-102 1mg 48% of patients in the GB-102 1 mg arm were rescue-free for at least 6 months Control of retinal thickness was consistent across all trial arms Mean best-corrected visual acuity with GB-102 1mg trended lower than aflibercept arm No
REDWOOD CITY, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate
REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vision-threatening diseases of the retina and optic nerve, today announced that Fred Guerard,